(5-(2-Amino-6-oxo-1H-purin-9(6H)-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl dihydrogen phosphate | 7586-40-5

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷酸
• 英文名称: (5-(2-Amino-6-oxo-1H-purin-9(6H)-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl dihydrogen phosphate
• 英文别名: 5′-guanosine monophosphate；guanosine-5-monophosphate；Guanosine-monophosphate；2-amino-9-(O⁵-phosphono-pentofuranosyl)-1,9-dihydro-purin-6-one；[5-(2-Amino-6-oxohydropurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen p hosphate；[5-(2-amino-6-oxo-1H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate
• CAS: 7586-40-5
• 化学式: C₁₀H₁₄N₅O₈P
• 分子量: 363.224
• InChiKey: RQFCJASXJCIDSX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -3.5
• 重原子数：
  24
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  202
• 氢给体数：
  6
• 氢受体数：
  10

反应信息

• 作为反应物：
  描述：

  (5-(2-Amino-6-oxo-1H-purin-9(6H)-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl dihydrogen phosphate 、 (Me4-ethylenediamine)palladium(II)(H2O)2(2+) 在 高氯酸 作用下， 生成
  参考文献：
  名称：

  Mechanistic information on the reaction of model palladium(II) complexes with purine nucleosides and 5′-nucleotides in reference to the antitumor activity of related platinum complexes

  摘要：

  The reaction of Pd(Me,en)Cl2 (Me4en=NNN',N'-tetramethylethylenediamine) with inosine and 5'-inosine monophosphate was studied as a function of chloride concentration and pH. Evidence for the formation of a 1:1 complex with these nucleophiles is presented, and the kinetic data indicate that Pd(Me4en)(Cl)H2O+ is the only reactive species under the selected experimental conditions. The results are compared to earlier data for the reactions of Pd(R4en)(H2O)22+ (R = H, Me, Et) with a series of nucleosides and 5'-nucleotides. The dependencies studied in this investigation allow some tentative extrapolations to conditions relevant for the antitumor activity of related Pt(II) complexes.

  DOI：

  10.1016/s0020-1693(00)92360-0

文献信息

• [EN] MRNA CAP ANALOGS AND METHODS OF MRNA CAPPING<br/>[FR] ANALOGUES DE COIFFES ARNM ET PROCÉDÉS DE COIFFAGE D'ARNM
  申请人：MODERNATX INC

  公开号：WO2017066793A1

  公开（公告）日：2017-04-20

  The present disclosure relates to cap analogs of formula (I) as defined in claim 1, which can result in high levels of capping efficiency and transcription and improved translation efficiencies. The present disclosure also relates to methods useful for preparing cap analogs and using mRNA species containing such analogs, as well as kits containing the novel cap analogs.

  本公开涉及公式（I）中定义的帽子类似物，其可以导致高水平的帽子效率和转录以及改善的翻译效率。本公开还涉及用于制备帽子类似物和使用包含此类类似物的mRNA物种的方法，以及包含新型帽子类似物的试剂盒。
• MODIFIED NUCLEOSIDE, NUCLEOTIDE, AND NUCLEIC ACID COMPOSITIONS
  申请人：MODERNA THERAPEUTICS

  公开号：US20130156849A1

  公开（公告）日：2013-06-20

  The present disclosure provides, inter alia, formulation compositions comprising modified nucleic acid molecules which may encode a protein, a protein precursor, or a partially or fully processed form of the protein or a protein precursor. The formulation composition may further include a modified nucleic acid molecule and a delivery agent. The present invention further provides nucleic acids useful for encoding polypeptides capable of modulating a cell's function and/or activity.

  本公开提供了包含修改的核酸分子的配方组合，这些核酸分子可能编码蛋白质、蛋白质前体或蛋白质或蛋白质前体的部分或完全加工形式的配方组合。该配方组合还可以包括一个修改的核酸分子和一个传递剂。本发明还提供了用于编码能够调节细胞功能和/或活性的多肽的核酸。
• Reactivity of kiteplatin with S-donor biomolecules and nucleotides
  作者：Emanuele Petruzzella、Nicola Margiotta、Giovanni Natile、James D. Hoeschele

  DOI：10.1039/c4dt01474j

  日期：——

  Interaction of kiteplatin with S-donors is investigated. Kiteplatin–glutathione adducts can further react with 5′-GMP in presence of O₂. This unique reaction may account for its activity toward oxaliplatin-resistant colon cancer.

  研究了铂络合物与硫氧化物的相互作用。Kiteplatin-谷胱甘肽加合物可以在氧气的存在下进一步与5'-GMP反应。这种独特的反应可能解释了它对氧化铂耐药结肠癌的活性。
• Basic Coordination Chemistry Relevant to DNA Adducts Formed by the Cisplatin Anticancer Drug. NMR Studies on Compounds with Sterically Crowded Chiral Ligands
  作者：Jamil S. Saad、Michele Benedetti、Giovanni Natile、Luigi G. Marzilli

  DOI：10.1021/ic100494f

  日期：2010.6.21

  group cisG N1H hydrogen bonding favors the ΛHT and the ΔHT conformers for 5′-GMP and 3′-GMP adducts, respectively. For both HT conformers of cis-PtA2G2 adducts, the G nucleobase plane normally cants with respect to the coordination plane in the same direction, left or right, for a given A2 chirality. In contrast, the results for Me4DABPtG2 adducts provide the first examples of a change in the canting

  Me 4 DAB Pt G 2与庞大的C 2对称手性二胺，Me 4 DAB（N，N，N '，N'-四甲基-2,3-二氨基丁烷在螯合物上具有R，R和S，S构型的加合物环C原子，G =鸟嘌呤衍生物），显示缓慢的构象异构体互换，并且可以通过NMR方法表征。该调查顺-PtA 2摹2由临床广泛使用的抗癌药[A 2 =二氨基环己烷，（NH 3）2 ]形成的加合物受到内部配位球附近低A 2团块允许的快速构象异构体互换的阻碍。Me 4 DAB Pt G 2加合物仅以头对尾（HT）构象异构体的混合物形式存在。没有观察到头对头（HH）顺应性。在我4 DAB其中HT手性是有利的（高差为手性显著影响小号，小号和ΛHT为[R ，- [R ）。对于简单的G配体，优选的HT构象体与不太优选的HT构象体的比例为〜2∶1。对于鸟苷单磷酸酯（GMP）配体，磷酸基团顺式G N1H氢键分别有利于5'-GMP和3'-GMP加合物的
• ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF
  申请人：Moderna Therapeutics, Inc.

  公开号：US20150167017A1

  公开（公告）日：2015-06-18

  The present disclosure provides alternative nucleosides, nucleotides, and nucleic acids, and methods of using them.

  本公开提供了替代核苷、核苷酸和核酸以及它们的使用方法。